S2Medical AB (S2M) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 9 Million ()

P/E

7.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.07

Return on Equity

8.02%

Price to Book

0.47

Revenue and Profits:

Net Sales:

8 Million

(Quarterly Results - Dec 2024)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.56%

6 Months

-50.0%

1 Year

13.68%

2 Years

-36.84%

3 Years

-95.36%

4 Years

-98.92%

5 Years

-99.4%

S2Medical AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

46.38%

EBIT Growth (5y)

9.09%

EBIT to Interest (avg)

-11.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

3.16

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

30.30%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.58

EV to EBIT

-1.60

EV to EBITDA

-1.95

EV to Capital Employed

0.55

EV to Sales

0.56

PEG Ratio

Dividend Yield

ROCE (Latest)

-34.20%

ROE (Latest)

8.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 165.52% vs -29.27% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -134.78% vs 762.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.70",
          "val2": "2.90",
          "chgp": "165.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-1.30",
          "chgp": "-84.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "6.90",
          "chgp": "-134.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-311.70%",
          "val2": "-539.90%",
          "chgp": "22.82%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 110.00% vs 48.94% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 121.15% vs 23.05% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.70",
          "val2": "7.00",
          "chgp": "110.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-14.70",
          "chgp": "88.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "7.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.80",
          "val2": "-22.70",
          "chgp": "121.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-162.80%",
          "val2": "-2,271.90%",
          "chgp": "210.91%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Dec'24

Jun'24

Change(%)

Net Sales

7.70

2.90

165.52%

Operating Profit (PBDIT) excl Other Income

-2.40

-1.30

-84.62%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.40

6.90

-134.78%

Operating Profit Margin (Excl OI)

-311.70%

-539.90%

22.82%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2024 is 165.52% vs -29.27% in Jun 2024

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -134.78% vs 762.50% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

14.70

7.00

110.00%

Operating Profit (PBDIT) excl Other Income

-1.70

-14.70

88.44%

Interest

0.00

7.40

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

4.80

-22.70

121.15%

Operating Profit Margin (Excl OI)

-162.80%

-2,271.90%

210.91%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 110.00% vs 48.94% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 121.15% vs 23.05% in Dec 2023

All Annual Results

Company CV

About S2Medical AB

S2Medical AB

Pharmaceuticals & Biotechnology

S2Medical AB (publ) is a Sweden-based medical technology company. The Company focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The Company's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The Company is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.

Company Coordinates

Company Details

Sunnorpsgatan 5 , LINKOPING None : 582 73

Tel: 46 8 7000050

http://www.s2m.se/

Registrar Details